Amgen stock tumbled nearly 3 percent on July 26, despite reporting an increase in its second quarter net income to $2.15 billion, bringing it up to $4.74 billion for the first half of 2017. Total revenues rose 2 percent, including $100 million in product sales and $22 million in other revenues, compared to the same…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
